Analyst vs AI Verdict
Wall Street
AI Expert Panel
Price Chart
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 19.8% | 19.8% | 19.8% | 19.8% | 21.8% | 21.8% |
| P/E (TTM) | 25.45 | 29.72 | 28.13 | 30.84 | 30.10 | 30.65 |
| Net Margin | 17.0% | 14.7% | 14.7% | 14.7% | 16.2% | 16.2% |
| Gross Margin | 82.0% | 82.1% | 82.1% | 82.1% | 81.9% | 81.9% |
| D/E Ratio | 73.43 | 73.43 | 73.43 | 73.43 | 71.11 | 71.11 |
| Current Ratio | 0.86 | 0.86 | 0.86 | 0.86 | 0.88 | 0.88 |
Company Summary
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; and a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
View full stock profile →More Signals for AZN
View all →Related News
View all →Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?
Exclusive-'No discussions' over AstraZeneca-Bristol Myers deal, senior source says
The $400 Billion Reason Bristol-Myers Squibb (BMY) Stock Is Up Today
Bristol Myers Squibb Stock Jumps on Reported Merger Talks With AstraZeneca
AstraZeneca shares slump after $400bn BMS merger rumours
Trade Outcome
Historical Stats
AZN Bounce Up
Signal Info
Disclaimer: This is an automated trading signal generated by AI analysis. It is not financial advice. Always do your own research before making investment decisions. Past performance does not guarantee future results.